Evgen Pharma PLC Notice of Preliminary Results (1623G)
May 25 2017 - 2:02AM
UK Regulatory
TIDMEVG
RNS Number : 1623G
Evgen Pharma PLC
25 May 2017
For immediate release 25 May 2017
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Notice of Preliminary Results
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, will announce its preliminary results for the year
ended 31 March 2017 on Tuesday 13 June 2017.
A meeting for analysts will be held at 11.00am on the morning of
the results announcement at the offices of Buchanan, 107 Cheapside,
London EC2V 6DN. For further information, or to register
attendance, please contact Buchanan at the contact details
below.
Enquiries:
Evgen Pharma plc c/o +44 (0) 20
Dr Stephen Franklin, CEO 7466 5000
Richard Moulson, CFO
www.evgen.com
Buchanan
Mark Court, Sophie Cowles, Stephanie +44 (0) 20
Watson 7466 5000
Northland Capital Partners Limited
Matthew Johnson, Gerry Beaney, Margarita
Mitropoulou (Corporate Finance)
John Howes and Rob Rees (Corporate +44 (0) 20
Broking) 3861 6625
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. It is also carrying out preclinical work in
multiple sclerosis and has a clinical interest in prostate cancer.
The Company's core technology is Sulforadex(R), a method for
synthesising and stabilising the naturally occurring compound
sulforaphane and novel proprietary analogues based on sulforaphane.
The lead product, SFX-01, is a patented composition of synthetic
sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire. It joined the AIM
market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORQZLFLDEFXBBB
(END) Dow Jones Newswires
May 25, 2017 02:02 ET (06:02 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2023 to Apr 2024